Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...5455565758596061626364...858859»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer. (Pubmed Central) -  Jun 19, 2024   
    Pathway enrichment analysis in hormone receptor-positive, human epidermal growth factor receptor 2-negative patients demonstrated differentially modulated pathways implicated in DNA repair and transcriptional regulation in those with reduced response to capecitabine/gemcitabine, and pathways associated with cell cycle regulation in those with reduced response to palbociclib. Our study shows that PDO-based functional precision medicine is a feasible and effective strategy for MBC treatment optimization and customization.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Preclinical, Journal, IO biomarker, Stroma:  Elimination of radiation-induced senescent cancer cells and stromal cells in (Pubmed Central) -  Jun 18, 2024   
    In antiproliferative activities and kinase inhibitory effects assays, we found that the antiproliferative effects of B01 were close to positive controls Palbociclib, with GI50 values of 4.87 NIR-PIT eliminates both senescent cancer and stromal cells in
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Nurtec ODT (rimegepant ODT) / Pfizer
    Combined use of rimegepant and eptinezumab for treatment of chronic migraine () -  Jun 18, 2024 - Abstract #AHS2024AHS_420;    
    The co-administration of gepants and CGRP targeted mAbs can be effective in reducing severity and frequency of chronic migraine headaches. Patient did not report any adverse side effects from the combined use of these medications.
  • ||||||||||  Which combination of comorbidity makes migraine treatment impossible? A graphical approach () -  Jun 18, 2024 - Abstract #AHS2024AHS_411;    
    Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
    Real-world effectiveness of intravenous eptinezumab in patients with chronic migraine and previous subcutaneous preventive migraine treatment () -  Jun 18, 2024 - Abstract #AHS2024AHS_385;    
    All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world patient survey study demonstrated that individuals with prior exposure to subcutaneous anti-CGRP monoclonal antibodies expressed high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Comprehensive assessment of erenumab efficacy in patients with high frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study () -  Jun 18, 2024 - Abstract #AHS2024AHS_340;    
    P4
    In this trial, participants treated with erenumab reported spending significantly fewer hours with a headache of moderate or severe pain intensity every month while also experiencing significantly lower impact of migraine on usual activities and measures of physical, social and emotional functioning. In addition, the EMBRACE trial provided confirmatory evidence to support that treatment with erenumab produces an enduring impact on residual migraine attacks with remaining events being less painful overall as measured by the significant reduction in the average peak pain intensity per attack and the average time spent with a moderate-to-severe headache on remaining recorded attacks as compared to placebo.
  • ||||||||||  umibecestat (CNP520) / Novartis, Amgen, Banner Alzheimer's Institute
    Journal:  Targeting key players in Alzheimer's disease: bioactive compounds from Moringa oleifera, Desmodium gangeticum, and Centella asiatica as potential therapeutics. (Pubmed Central) -  Jun 18, 2024   
    Astilbin, Delphinidin 3-glucoside, and kaempferol 7-O-glucoside showed good binding affinity and structural stability when compared to other compounds and the control CNP520...Through microsecond simulation, it was found that Astilbin alters BACE1's behavior and induces conformational rearrangements. Thus, this study opens a gateway to inhibit the activity of BACE1 protein through Astilbin thereby disclosing the possibility of managing Alzheimer's Disease.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Publication Trends in Osteoporosis Treatment: A 20-Year Bibliometric Analysis. (Pubmed Central) -  Jun 18, 2024   
    The effector mechanism of anti-osteoporosis medications could be future hot spots in osteoporosis research. We believe that our study is a valuable guide for clinicians related to the global outputs of osteoporosis treatment.
  • ||||||||||  oprozomib (ONX 0912) / Amgen
    Preclinical, Journal:  Tissue-, region-, and gene-specific induction of microsomal epoxide hydrolase expression and activity in the mouse intestine by arsenic in drinking water. (Pubmed Central) -  Jun 17, 2024   
    The induction of intestinal mEH was accompanied by increases in microsomal enzymatic activities toward a model mEH substrate, cis-stilbene oxide, and an epoxide-containing drug, oprozomib, in vitro, and by increases in the levels of PR-176, the main hydrolysis metabolite of oprozomib, in the proximal small intestine of oprozomib-treated mice...The small intestinal epithelial cells are the main site of absorption of ingested arsenic, but they are not well characterized for arsenic exposure-related changes. This study identified gene expression changes in the small intestine that may be mechanistically linked to the adverse effects of arsenic exposure and possible interactions between arsenic ingestion and the pharmacokinetics of epoxide-containing drugs in vivo.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab-induced bone changes in a child: a case report. (Pubmed Central) -  Jun 17, 2024   
    This study identified gene expression changes in the small intestine that may be mechanistically linked to the adverse effects of arsenic exposure and possible interactions between arsenic ingestion and the pharmacokinetics of epoxide-containing drugs in vivo. We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer. (Pubmed Central) -  Jun 17, 2024   
    We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw. Although grade 3-4 toxicity and dose reductions occurred frequently, most were expected and managed by dose reductions, showing that palbociclib is generally well tolerated and thus represents a valuable treatment option in the older population.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Retrospective data, Journal, Metastases:  First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN. (Pubmed Central) -  Jun 17, 2024   
    P=N/A
    Although grade 3-4 toxicity and dose reductions occurred frequently, most were expected and managed by dose reductions, showing that palbociclib is generally well tolerated and thus represents a valuable treatment option in the older population. These findings, consistent with those from clinical trials, support use of palbociclib plus ET as 1
  • ||||||||||  MRTX1133 / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal:  Inhibition of GTPase KRASG12D: a review of patent literature. (Pubmed Central) -  Jun 17, 2024   
    It is important to note, however, that understanding the mechanisms of acquired resistance caused by KRAS inhibition and developing additional combination therapies is crucial. Moreover, seeking covalent inhibition of KRASG12D also holds significant potential.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    Journal:  A Refractory Case of Rapidly Progressive Glomerulonephritis Due to Microscopic Polyangiitis. (Pubmed Central) -  Jun 17, 2024   
    In addition, when used in place of steroids, they reduce the morbidity associated with cumulative glucocorticoid toxicity. For patients with ANCA-associated vasculitis refractory to standard therapies, targeted immunomodulators such as avacopan should be considered as alternative or adjunct therapy.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Tezepelumab in a case of severe asthma exacerbation and influenza-pneumonia on VV-ECMO. (Pubmed Central) -  Jun 17, 2024   
    After administration of a single dose Tezepelumab, a novel TLSP-inhibitor, and otherwise unchanged therapy we documented a significant reduction in intrinsic PEEP measured via a naso-gastric balloon catheter and a narrowing in the expiratory flow curve of the ventilator within 24 hours. The consecutive ventilatory improvement allowed the successful weaning from veno-venous ECMO therapy and invasive ventilation.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Establishment of Blinatumomab Home Administration Transition Program Using CADD-Legacy (Pubmed Central) -  Jun 17, 2024   
    The program recommended that repeated overnight stays with continued hospitalization would help patients safely transition to home administration of blinatumomab. Pediatric patients who do not attend school, such as preschoolers, or who return to their original school, can be transited to an outpatient setting if people caring for pediatric patients, including teachers in the school, are educated.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone (clinicaltrials.gov) -  Jun 17, 2024   
    P4,  N=70, Recruiting, 
    We advocate for an interdisciplinary approach and further research into tailored prevention and management of osteonecrosis in cancer survivors. Trial completion date: Jan 2023 --> Jun 2026 | Trial primary completion date: Jul 2022 --> Apr 2026
  • ||||||||||  Review, Journal:  Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment. (Pubmed Central) -  Jun 16, 2024   
    Additionally, molecular docking studies with compounds under clinical trial and patents filed on pyrimidine based CDK inhibitors in cancer treatment are included. This review serves as a valuable resource for further development of CDK kinase inhibitors for cancer treatment, offering insights into their efficacy, specificity, and potential clinical applications.
  • ||||||||||  Review, Journal:  Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity. (Pubmed Central) -  Jun 15, 2024   
    Although many biologics presently indicated as add-on maintenance therapy for severe asthma exhibit efficacy in obese asthmatics, other phenotypes of asthma co-existing with obesity may be refractory to these medications. Thus, to improve quality of life and asthma control, it is imperative to identify therapeutic options for all existing phenotypes of obese asthma.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Bone health in patients with inflammatory bowel disease. (Pubmed Central) -  Jun 14, 2024   
    From a therapeutic perspective, besides good disease control, vitamin D supplementation and glucocorticoid sparing, several specific osteological options are available: bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab), parathyroid hormone (PTH) analogues and selective estrogen receptor modulators. This review provides an overview of the pathophysiology, diagnosis, prevention and treatment of IBD-associated bone loss.
  • ||||||||||  Prolia (denosumab) / Amgen, Recalbon (minodronic acid) / Ono Pharma
    Journal:  Atypical Fracture of the Scapular Spine: A Case Report. (Pubmed Central) -  Jun 14, 2024   
    We describe an atypical fracture of the scapular spine in a 92-year-old Japanese woman with osteoporosis who had been treated with minodronate for ~7 years. Although the dislocation of the fracture site remained after conservative treatment, there was no obstacle to her daily life.